you can get a better handle on the ryan white program jsut by knowing how many pts got their HIV meds through them which was about 150K. so that equates to about 15M in covered lives using a 1% prevalence rate for HCV in the US. that however doesnt tell the whole story still because about half of pts don't kwo they are HCV positive whereas all the pts in this program know their HCV status - so you can actually equate this to 30M covered lives. i would then adjust downward given the discount to them is going to be larger than to private payers. then of course you have to wonder what proportion of coinfected will get treatment versus mono infected (i don't really knwo the answer to this jsut a hunch that it may be higher since coinfection can exacerbate liver fibrosis but some woudl have to adjust their HIV drugs too so i don't really know)
I think way too much about this crap given it is jsut a hobby!
BTW it is worth mentioning here that GILD has done a pretty good job too between CVS aetna anthem etc. i couunt 77M covered lives so GIDL has 24% of the US population locked down, ABBV somewhat less and a disporportionate share that will be more heavily discounted (ryan white and medicaid) but certainly holding their own
Market Data 
Markets 
AI
